Skip to main content

Table 3 Univariate and multivaritate analyses of overall survival and disease-free survival of patients with ESCC

From: Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma

 

Overall survival

P

Disease-free survival

P

HR (95% CI)

 

HR (95% CI)

 

Univariate analysis

 Gender (Male vs. female)

0.290 (0.040–2.124)

0.223

0.345 (0.047–2.517)

0.294

 Age (y) (< 60 vs. ≥60)

0.786 (0.401–1.507)

0.469

0755 (0.401–1.423)

0.385

 Alcohol (Light vs. Heavy)

1.711 (0.873–3.354)

0.118

1.825 (0.940–3.543)

0.075

 Smoking (Light vs. Heavy)

1.261 (0.664–2.395)

0.479

1.239 (0.664–2.311)

0.501

 Stage (I/II vs. III/IV)

1.421 (0.744–2.714)

0.288

1.559 (0.830–2.927)

0.167

 Differentiation (WD vs. MD/PD)

1.425 (0.641–3.170)

0.385

1.418 (0.667–3.018)

0.364

 Location (upper/middle vs. lower)

1.139 (0.560–2.316)

0.720

1.305 (0.658–2.591)

0.446

 Adjuvant therapy

1.437 (0.698–2.960)

0.325

1.814 (0.916–3.593)

0.088

 Resection margin (R0 vs. R1)

1.050 (0.370–2.976)

0.927

1.286 (0.454–3.638)

0.636

 Vascular invasion

1.992 (1.009–3.934)

0.047

1.932 (0.992–3.765)

0.053

 Lymphatic invasion

1.856 (0.944–3.648)

0.073

1.905 (0.989–3.671)

0.054

 Perineural invasion

1.951 (0.934–4.073)

0.075

2.083 (0.998–4.345)

0.051

 Dysplasia

0.574 (0.296–1.115)

0.101

0.478 (0.716–3.064)

0.031

 PD-L1 (negative vs. positive)

0.084 (0.256–1.090)

0.078

0.458 (0.222–0.944)

0.034

 MSI/dMMR

1.667 (0.780–3.564)

0.187

1.804 (0.879–3.704)

0.108

 PIK3CA mutation

1.876 (0.777–4.530)

0.162

1.818 (0.756–4.373)

0.182

Multivariate analysis

 Vascular invasion

1.818 (0.824–4.009)

0.139

1.622 (0.726–3.623)

0.239

 Lymphatic invasion

1.557 (0.707–3.429)

0.271

1.725 (0.747–3.983)

0.202

 Perineural invasion

1.435(0.646–3.188)

0.376

1.069(0.449–2.544)

0.880

 PD-L1 (negative vs. positive)

0.416 (0.196–0.885)

0.023

0.379 (0.174–0.824)

0.014

 Alcohol (Light vs. Heavy)

–

–

1.792(0.868–3.701)

0.115

 Adjuvant therapy

–

–

2.009(0.896–4.504)

0.090

 Dysplasia

–

–

0.701(0.341–1.444)

0.336

  1. ESCC esophageal squamous cell carcinoma, HR hazard ratio, CI 95% confidence interval, WD well-differentiation, MD moderately-differentiation, PD poorly-differentiation, PD-L1 programmed death ligand-1, MSI microsatellite instability, dMMR deficient mismatch repair
Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us